CAMBRIDGE, UK--Gemini Genomics, formerly Gemini Holdings, announced that it has entered into a two-year drug target identification collaboration with CuraGen to accelerate drug discovery. CuraGen and Gemini scientists will work together to associate CuraGen's thousands of single-nucleotide polymorphisms with disease traits derived from Gemini's database of clinical populations.
Gemini changed its name late last month to reflect its clinical genomics approach to identifying disease genes.
Separately, CuraGen expanded its drug discovery and pharmacogenomics collaboration with COR Therapeutics of South San Francisco. The companies will use CuraGen's PathCalling proteomics technology and bioinformatics systems to create an annotated database of protein-protein interactions derived from cardiovascular endothelial cells.